Positioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease

Positioning PI3K Inhibitors in the CLL/SLL Treatment Paradigm: New Options for Relapsed/Refractory Disease

On-Demand Webcast

John N. Allan, MD
Weill Cornell Medicine
New York, New York

Matthew S. Davids, MD, MMSc
Dana-Farber Cancer Institute
Boston, Massachusetts

Silvia Deaglio, MD, PhD
University of Turin
Turin, Italy

Richard R. Furman, MD
Weill Cornell Medicine
New York, New York

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Thomas J. Kipps, MD, PhD
University of California
La Jolla, California

Jennifer A. Woyach, MD
Ohio State University
Columbus, Ohio

Target Audience

This activity is intended for hematologists/oncologists, PAs, NPs, nurses, and pharmacists who specialize in hematology, as well as other HCPs who care for patients with hematologic malignancies.


Advances in understanding the pathophysiologic mechanisms of hematologic malignancies in recent years have led to the advent of new and highly effective medications for the treatment of the many subtypes of heterogenic and often deadly diseases, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). CLL/SLL is the most prevalent type of adult leukemia in the United States, with about 20,700 new cases and 3,900 deaths per year. Treatment challenges are common with CLL/SLL.

For the treatment of CLL/SLL, a number of targeted therapies have emerged, but the diversity of these targeted therapies, with different characteristics even among agents within the same therapeutic class, generates new challenges for their optimal placement in therapeutic paradigms. Moreover, the data pool surrounding targeted CLL/SLL therapy is continually evolving, featuring expanded indications for specific relapsed/refractory (R/R) patient populations, next-generation agents with improved efficacy and safety profiles, including phosphoinositide 3-kinase (PI3K) inhibitors, and new combination strategies that are poised to further advance outcomes for patients with CLL/SLL. In light of this rapidly changing treatment landscape, hematologists and oncologists must overcome a number of clinical practice gaps that may interfere with providing optimal patient care.

This webcast aims to update clinicians on the latest clinical trial data surrounding new therapies and combinations of therapies for the treatment of CLL/SLL; optimal sequencing based on current data; within-class differences among new targeted therapies; and the latest research on mechanisms of side effects and strategies to allow patients to remain on treatment.


Upon successful completion of this educational activity, participants should be better able to:

  1. Summarize the most recent clinical trial data for PI3K-targeted medications approved for the treatment of R/R CLL/SLL
  2. Discuss patient factors and targeted drug characteristics that will influence sequencing decisions in the treatment of patients with R/R CLL/SLL
  3. Manage the most common side effects/toxicities of PI3K inhibitors that can interfere with optimal treatment outcomes for patients with R/R CLL/SLL in clinical practice

Release Date: December 31, 2019

Expiration Date: December 31, 2020

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.


Supported by an educational grant from: Verastem Oncology.


 In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


NACCME designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 4.5 AAPA Category 1 credit(s).

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 4.5 contact hours.

Provider approved by the California Board of Registered Nursing, Provider #13255 for 4.5 contact hours.


This knowledge-based activity (JA0006201-9999-20-043-H01-P) is approved for 4.5 contact hours (0.45 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises John N. Allan, MD, Matthew S. Davids, MD, MMSc, Silvia Deaglio, MD, PhD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, Jennifer A. Woyach, MD; and Chris Bolwell, Lara Gray, and Griselda Zuccarino-Catania Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant financial relationships that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve any conflicts. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

John N. Allan, MD, reports that he is a consultant for AbbVie, AstraZeneca, Cellectar, Genentech, Pharmacyclics, and Suneis; has received grant or research support from Janssen; and has received other financial support from AstraZeneca and Janssen.

Matthew S. Davids, MD, MMS, reports that he is a consultant for AbbVie, Acerta Pharma, Adaptive Biotechnologies, Genentech, Janssen, MEI Pharma, Research to Practice, Syros Pharmaceuticals, TG Therapeutics, and Verastem Oncology; and has received grant or research support from Acerta Pharma, Ascentage Pharma, Genentech, MEI Pharma, Surface Oncology, TG Therapeutics, and Verastem Oncology.

Silvia Deaglio, MD, PhD, reports that she has received grant or research support from Sunesis iTeos, VelosBio, and Verastem Inc.

Richard R. Furman, MD, reports that he is a consultant Abbvie, Acerta, AstraZeneca, Beigene, Genentech, Incyte, Janssen, Loxo Oncology, Oncotracker, Pharmacyclics, Sunesis, TG Therapeutics, and Verastem; has received grant or research support from Acerta, AstraZeneca, and TG Therapeutics; and has received other financial support from Incyte.

Neil E. Kay, MD, reports that he is a consultant for Agios Pharm, Astra Zeneca, Celgene, Cytomx Therapeutics, Dava Oncology, Infinity Pharm, Juno Therapeutics, MorphoSys, Pharmacyclics, and Rigel; and has received grant or research support from Acerta Pharma BV, MEI Pharma, Pharmacyclics, and Tolero Pharmaceuticals.

Thomas J. Kipps, MD, PhD, reports that he is a consultant for Abbvie, Genentech, Pharmacyclics, Octernal, Inc., and VelosBio; has received grant or research support from Abbvie, Pharmacyclics, Genentech, Oncternal, Inc., VelosBio; is a speaker for Abbvie, Genentech, and Pharmacyclics; and has received other financial support from Oncternal, Inc.

Jennifer A. Woyach, MD, has received grant or research support from Abbvie, Acerta, Janssen, Loxo, Karyopharm, Morphosys, and Pharmacyclics; and received other financial support from Janssen and Pharmacyclics.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Griselda Zuccarino-Catania disclosed that her spouse is employed by Janssen Pharmaceuticals, Inc.

Lara Gray disclosed no relevant financial relationships with any commercial interests.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME or Imedex.

Privacy Policy

NACCME and Imedex protect the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME, Imedex and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME and Imedex maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2019 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.